Novaliq
Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first and only water-free technology worldwide for ophthalmology products. With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye diseases. Two EyeSol® entities have been developed to distinctly target either predominantly aqueous or evaporative disease and potentially break the vicious circle of DED. Both are currently in phase 3 development: >> NOV03 (100% perfluorohexyloctane) is the first drug developed to treat evaporative DED associated with Meibomian gland dysfunction in a highly effective way. >> CyclASol®, an ophthalmic solution of 0.1% cyclosporine A in EyeSol®, is an anti-inflammatory and immunomodulating drug for the treatment of aqueous deficient DED. Both investigational drugs have shown superior clinical benefit, with an early onset of action and an excellent tolerability profile. NovaTears® water-free eye drops for dry eye disease have CE Marking and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies. More on www.novaliq.com.
Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first and only water-free technology worldwide for ophthalmology products. With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye diseases. Two EyeSol® entities have been developed to distinctly target either predominantly aqueous or evaporative disease and potentially break the vicious circle of DED. Both are currently in phase 3 development: >> NOV03 (100% perfluorohexyloctane) is the first drug developed to treat evaporative DED associated with Meibomian gland dysfunction in a highly effective way. >> CyclASol®, an ophthalmic solution of 0.1% cyclosporine A in EyeSol®, is an anti-inflammatory and immunomodulating drug for the treatment of aqueous deficient DED. Both investigational drugs have shown superior clinical benefit, with an early onset of action and an excellent tolerability profile. NovaTears® water-free eye drops for dry eye disease have CE Marking and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies. More on www.novaliq.com.
Novaliq has raised $15.0M across 1 round. Its most recent round was a Venture - Series Unknown of $15.0M in Apr 2022. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Novaliq is featured in
Similar companies
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of sustainable and food alternatives.
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and pathogens in food.
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is dedicated to researching Tumor-Associated Carbohydrate Antigens (TACAs) as a potential new target for cancer therapy. TACAs are expressed specifically in tumors due to abnormal glycosylation, and contribute to processes like metastasis, angiogenesis, and immune suppression. Tacalyx utilizes advanced carbohydrate synthesis technology to create pure TACA structures, which are then used to develop antibodies for innovative cancer treatments.
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and scalable production.
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their solubility, stability, and absorption. Our OPTISOLV® Technology helps deliver natural actives into food, nutraceuticals, pharmaceuticals, and personal care products — more effectively and efficiently. Our goal is to support brands in creating their next product innovation. Developed in Germany. Produced in Europe.
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored expression systems for enzymes from picoliter to large-scale fermentation. They are building on their experience in engineering a wide range of industrial organisms including bacteria, yeast, and filamentous fungi. Their customized enzyme solutions are applicable across industries such as circular economy, food, and feed. Picea Biosolutions is headquartered in Offenburg, Baden-Wurttemberg and was founded in 2022.
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity. The company's mission is to provide cancer patients with not only safe but also inexpensive immunotherapy, as well as to produce immunostimulatory drugs capable of preventing infectious illnesses.
iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.